BURLINGTON, Mass., Feb. 28 /PRNewswire-FirstCall/ --
Palomar Medical Technologies Inc (Nasdaq: PMTI) today announced that the
Palomar SLP1000(TM) Diode Laser System was cleared by the FDA for treatment of
Pseudofolliculitis Barbae (PFB). The system has already been cleared for
permanent hair reduction and treatment of vascular lesions. Patients who
suffer from ingrown hair on the face or neck as a result of shaving or
plucking now have a new, highly effective treatment option.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO )
Pseudofolliculitis barbae is a common skin disorder that occurs primarily
in African Americans, with over 50% incidence within this population, and
other persons with thick, curly hair. The problem occurs when shaved hairs
grow back under the skin, producing inflammation, irritation and,
occasionally, keloidal scars. Men and women with PFB often refrain from
shaving in order to reduce the severity of their condition. Topical steroids,
antibiotics, and exfoliating agents may reduce the severity as well, but their
benefits tend to be short-lived. The Palomar SLP1000 system, however, provides
sustained relief by reducing and thinning the hair. The SLP1000 system uses a
super-long pulsewidth and pre-, parallel, and post-contact cooling to provide
safe and effective treatments on all skin types; hence, the laser can be
especially helpful for dark-skinned patients.
Oscar Saffold, M.D., of Cleveland, OH, commented "I've been using the
Palomar SLP1000 laser system for hair removal and treatment of PFB for over a
year. It is clear to me that for people with dark skin (skin type V-VI) this
system is safe and effective. I have treated over 150 patients with remarkable
results; patients demonstrate 95 percent hair reduction and clearance of PFB
nine-months after the last treatment."
The Palomar SLP1000 system, the recently introduced Palomar EsteLux(TM)
light-based system for hair, pigmented lesion and vascular lesion removal and
the Palomar Q-YAG 5(TM) laser system for tattoo and pigmented lesion removal
were demonstrated this week at the American Academy of Dermatology (AAD)
meeting. This suite of products attracted a great deal of interest in the
Palomar booth from the Dermatologists. As a result, numerous leads were
accumulated and a number of orders were received for the products.
About Palomar Medical Technologies Inc: Palomar is the leading researcher
and developer of laser/light based systems for hair removal and other cosmetic
treatments and is the first company to obtain clearance from the FDA for
"permanent hair reduction." Palomar systems have been installed in practices
worldwide, and hundreds of thousands of treatments have been performed. New
and exciting indications are being tested to further advance the hair removal
market and other cosmetic applications including fat reduction, acne treatment
and skin rejuvenation.
To get more information regarding Palomar and its products, please visit
Palomar's web site at http://www.palmed.com. Also, to continue to receive the most
up-to-date information and latest news on Palomar as it happens, sign up to
receive automatic e-mail alerts by going to the e-mail alerts page in the
Investor Relations' section of the web site.
With the exception of the historical information contained in this
release, the matters described herein contain forward-looking statements,
including but not limited to statements relating to new markets, development
and introduction of new products, and financial projections that involve risk
and uncertainties that may individually or mutually impact the matters herein,
and cause actual results, events and performance to differ materially from
such forward-looking statements. These risk factors include, but are not
limited to, results of future operations, technological difficulties in
developing or introducing new products, the results of future research, lack
of product demand and market acceptance for current and future products, the
effect of economic conditions, the impact of competitive products and pricing,
governmental regulations with respect to medical devices, including whether
FDA clearance will be obtained for future products, the results of litigation,
potential infringement of third-party intellectual property rights, and/or
other factors, which are detailed from time to time in the company's SEC
reports, including the report on Form 10-K for the year ended December 31,
2000 and the Company's quarterly reports on Form 10-Q. Readers are cautioned
not to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. The company undertakes no obligation to release
publicly the result of any revisions to these forward-looking statements that
may be made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
Contact:
Paul S. Weiner,
Treasurer
781-993-2411 or ir@palmed.com
SOURCE Palomar Medical Technologies, Inc.
 back to top
Related links:
http://www.palmed.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000308/PMTILOGO
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/107555.html
CONTACT:
Paul S. Weiner, Treasurer of Palomar,
+1-781-993-2411, ir@palmed.com
|
